AbCellera Biologics Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$1.69 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2023-02-21
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2021-03-31 was $1.92M, a 34.08% increase year-over-year.
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-03-31 was $1.44M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was -$1.69M, a 164.89% decline from fiscal 2021.
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2021 was $2.60M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2020 was -$1.47M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2019 was -$849.00K.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|
| 2022-12-31 | -$1.69M 10-K · filed 2023-02-21 | |
| 2021-12-31 | $2.60M 10-K · filed 2023-02-21 | |
| 2021-03-31 | $1.92M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$1.47M 10-K · filed 2023-02-21 | |
| 2020-03-31 | $1.44M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | -$849.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |